Abstract 4887
Background
Adenoid cystic carcinoma (ACC) is a rare salivary gland tumor, comprising less than 1% of head and neck neoplasms. Adjuvant radiotherapy (aRT) is suggested for late-stage disease (stage III or IV); however, recent evidence suggests that it may be associated with improved survival even for early-stage disease. Moreover, the prognostic significance of tumor location on overall (OS) and ACC-specific (ACC-S) survival is unclear. We sought to address these knowledge gaps via analyses of the Surveillance, Epidemiology and End Results (SEER) database.
Methods
Intraoral minor (m) and major (M) ACCs from the SEER database (1973-2015) were selected for analysis. Information on age, sex, race, site, stage, treatment and survival was retrieved. The associations of tumor site and aRT with OS and ACC-S were estimated using hazard ratios (HR) and corresponding 95% confidence intervals (CI) obtained via Cox regression models adjusted for covariates as appropriate. Analyses were done using Stata 15.1 (StataCorp LP, College Station, TX).
Results
There were 635 minor and 1,064 major (parotid: n = 547, submandibular: n = 470, sublingual: n = 47) ACC cases included in the analyses. Late-stage patients (49% of total) were significantly more likely to have received aRT (76% vs. 66%; P < 0.01) compared to those with early-stage disease. Submandibular was the only tumour site that demonstrated statistically significant survival differences compared to the other sites; i.e., worse OS (HR = 1.4; 95% CI = 1.1-1.8) and ACC-S (HR = 1.7; 95% CI = 1.2-2.3) compared to minor ACCs. This difference was only evident for late-stage tumours: stage IV submandibular cases had worse OS (HR = 2.1; 95% CI = 1.5-2.8) and ACC-S (HR = 2.4; 95% CI = 1.7-3.4) compared to stage IV minor ACCs. Overall, aRT was associated with better OS (HR = 0.7; 95% CI = 0.6-0.9) and ACC-S (HR = 0.8; 95% CI = 0.6-1.1). This beneficial effect was more pronounced and statistically confirmed only in stage IV disease.
Conclusions
These results, based on SEER data, suggest that aRT is associated with favorable survival only in late-stage ACC and that, among these late-stage tumors, submandibular gland ACCs have substantially worse prognosis than other sites, irrespective of aRT.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Academy of Athens PhD Scholarship to Jason Tasoulas; UNC Lineberger Tier 3 Developmental Award funds and the University Cancer Research Fund to A.L. Amelio.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
3524 - Cabazitaxel For Octogenarian Patients With Metastatic Castration-Resistant Prostate Cancer (MCRPC).
Presenter: Paolo Tralongo
Session: Poster Display session 3
Resources:
Abstract
5637 - External Validation of a Prognostic Score in First-Line Metastastic Castration-Resistant Prostate Cancer (mCRPC)
Presenter: David Lorente
Session: Poster Display session 3
Resources:
Abstract
3228 - Treatment outcomes of 3rd treatment in a real-world metastatic castration resistant prostate cancer (mCRPC) population: results from the Dutch CAPRI-registry
Presenter: Jessica Notohardjo
Session: Poster Display session 3
Resources:
Abstract
4695 - Pelvic lymph node dissection and its extent on survival benefit in prostate cancer patients with a risk of lymph node invasion>5%: a propensity score matching analysis from SEER database
Presenter: Junru Chen
Session: Poster Display session 3
Resources:
Abstract
4438 - Multi-institutional evaluation of therapeutic management for oligometastatic cancer prostate recurrence with choline-PET/CT
Presenter: Morgane Guibert-broudic
Session: Poster Display session 3
Resources:
Abstract
4574 - Safety of new androgen receptor inhibitors (ARi) in patients with nonmetastatic castration-resistant prostate cancer (nmCRPC): a network meta-analysis of randomized controlled trials (RCT)
Presenter: Amelia Altavilla
Session: Poster Display session 3
Resources:
Abstract
3816 - Real-world use of radium-223 for treatment of metastatic castration resistant-prostate cancer (mCRPC): results from the Dutch CAPRI registry
Presenter: Malou Kuppen
Session: Poster Display session 3
Resources:
Abstract
5180 - A phase 2a study of radium-223 dichloride (Ra-223) alone or in combination with abiraterone acetate or enzalutamide in metastatic castration-resistant prostate cancer (mCRPC)
Presenter: Daniel Petrylak
Session: Poster Display session 3
Resources:
Abstract
1067 - Adding ADT to PSMA-PET/CT-guided SBRT for oligometastatic prostate cancer improves distant progression-free survival
Presenter: Carole Mercier
Session: Poster Display session 3
Resources:
Abstract
5529 - Safety and efficacy of Ac-225-PSMA-617 in metastatic castration resistant prostate cancer (mCRPC) after failure of Lu-177-PSMA
Presenter: Robert Tauber
Session: Poster Display session 3
Resources:
Abstract